Latest Clinical News

Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer (02-28-2019)

Results from the trial showed a significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) for the treatment of BRCA-mutated pancreatic cancer. POLO is a randomised, double-blinded, placebo-controlled... Continue Reading

Isatuximab – Promising for Treatment of Myeloma (02-25-2019)

A phase 3 comparative clinical trial evaluating Isatuximab has met the primary endpoint of delaying cancer progression in patients with relapsed/refractory multiple myeloma. Multiple myeloma is the second most common hematologic malignancy, with more... Continue Reading

Keytruda Approved for Treatment of Stage III Melanoma (02-21-2019)

The U.S. Food and Drug Administration (FDA) has approved Keytruda for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete surgical resection. Adjuvant Therapy in Melanoma Melanoma is separated into five... Continue Reading

FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer (02-18-2019)

The Food and Drug Administration (FDA) approved the immunotherapy drugs Opdivo and Yervoy in combination as an initial, or first-line, treatment for patients with advanced kidney cancer whose disease has an intermediate or poor prognosis. This is the... Continue Reading

Keytruda Plus Inlyta Improves Survival Compared ot Sutent for Treatment of Advanced Kidney Cancer (02-18-2019)

Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 targeted immunotherapy Keytruda (pembrolizumab) and the VEGF-targeted tyrosine kinase inhibitor Inlyta (axitinib) improved overall... Continue Reading

Personalized Vaccine to be Tested in Patients with Kidney Cancer (02-13-2019)

By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving... Continue Reading

Adjuvant Taxotere Doesn’t Improve Outcomes in Early Stage High Risk Prostate Cancer (02-11-2019)

Patients with high-risk, non-metastatic prostate cancer saw no survival advantage and no delay in metastases with the addition of adjuvant docetaxel to androgen deprivation therapy (ADT), according to the results of a pivotal clinical randomized trial... Continue Reading

Personalized Vaccine to be Tested in Patients with Kidney Cancer (01-29-2019)

By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving... Continue Reading

TVEC-Genetically Modified Virus Injection into Tumor – A Valid Treatment for Metastatic Melanoma (01-25-2019)

Results published in the Journal of the American College of Surgeons show sustained effectiveness of disease response and favorable side effect profile. CHICAGO (January 25, 2019): Injection of a genetically modified virus that induces the body’s own... Continue Reading

Targeted Radiation with 177Lu-PSMA-617 is Promising Treatment for Advanced Prostate Cancer (12-31-2018)

177Lu-PSMA-617 is a member of a new class of drugs that deliver radiation directly to tumor cells to obliterate them. These targeted radiation treatments consist of a radioactive isotope attached to a molecule that specifically targets tumor cells. In... Continue Reading

Immunotherapy Offers New Hope in Triple Negative Breast Cancer (12-28-2018)

Results from the Impassion 130 clinical trial published in the New England Journal of Medicine have demonstrated that immunotherapy can improve survival in breast cancer, especially in anti-programmed cell death ligand 1 (PD-1+) patients.  The results... Continue Reading

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications (12-21-2018)

The FDA has approved Celltrion and Teva’s Herzuma (trastuzumab-pkrb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer. Herzuma is the second oncology biosimilar approval in the United States in the past... Continue Reading

« Previous PageNext Page »